Solventum Corp
SOLV- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001964738
No open-market purchases or sales by Solventum Corp insiders were filed in the last 90 days; 885 institutions reported holding it in 13F filings for Q2 2026, worth $9.84B in total; Trian Fund Management is the only superinvestor holding it.
13F holders, Q1 2026
Institutional positions in Solventum Corp as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 885
- −43 vs. Q4 2025
- Shares held
- 128.7M
- +21.6M (+20.2%) vs. Q4 2025
- Total value
- $8.41B
- −$80.1M (−0.9%) vs. Q4 2025
- New holders
- 82
- 276 more added
- Sold out
- 125
- 282 more reduced
14 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SOLV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 885 | $9.84B |
| Q1 2026 | 885 | $8.41B |
| Q4 2025 | 942 | $9.99B |
| Q3 2025 | 873 | $8.90B |
| Q2 2025 | 892 | $8.70B |
| Q1 2025 | 919 | $8.69B |
| Q4 2024 | 946 | $7.28B |
| Q3 2024 | 944 | $7.48B |
| Q2 2024 | 909 | $5.57B |
| Q1 2024 | 67 | $152.5M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Solventum Corp; share changes are against Q4 2025.